

SECURITIES AND EXCHANGE COMMISSION

FORM 4

Statement of changes in beneficial ownership of securities

Filing Date: **2013-01-11** | Period of Report: **2013-01-09**
SEC Accession No. [0001144204-13-001956](#)

([HTML Version](#) on [secdatabase.com](#))

REPORTING OWNER

ENRIGHT PATRICK G

CIK: **1253886**

Type: **4** | Act: **34** | File No.: **001-33500** | Film No.: **13525798**

Mailing Address
CO LONGITUDE CAPITAL
PARTNERS LLC
800 EL CAMINO REAL,
SUITE 220
MENLO PARK CA 94025

ISSUER

Jazz Pharmaceuticals plc

CIK: **1232524** | IRS No.: **981032470** | State of Incorp.: **L2** | Fiscal Year End: **1231**
SIC: **2834** Pharmaceutical preparations

Mailing Address
4TH FLOOR, CONNAUGHT
HOUSE
ONE BURLINGTON ROAD
DUBLIN L2 4

Business Address
4TH FLOOR, CONNAUGHT
HOUSE
ONE BURLINGTON ROAD
DUBLIN L2 4
353-1-634-4183

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: 02/28/2011
Estimated average burden hours per response 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ENRIGHT PATRICK G			2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/09/2013			
C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220			4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person	
(Street) MENLO PARK, CA 94025						
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	01/09/2013		<u>S</u>		5,783 ⁽¹⁾	D	\$56.5164 ⁽²⁾	1,677,857	I	By Longitude Venture Partners, L.P. ⁽⁶⁾
Ordinary Shares	01/09/2013		<u>S</u>		117 ⁽¹⁾	D	\$56.5165 ⁽³⁾	33,635	I	By Longitude Capital Associates, L.P. ⁽⁶⁾
Ordinary Shares	01/10/2013		<u>S</u>		35,216 ⁽¹⁾	D	\$56.5244 ⁽⁴⁾	1,642,641	I	By Longitude Venture Partners, L.P. ⁽⁶⁾
Ordinary Shares	01/10/2013		<u>S</u>		706 ⁽¹⁾	D	\$56.5246 ⁽⁵⁾	32,929	I	By Longitude Capital Associates, L.P. ⁽⁶⁾
Ordinary Shares								2,250 ⁽⁷⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

1. Securities were sold pursuant to a 10b5-1 trading plan.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.50 to \$56.61, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.50 to \$56.61, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.50 to \$56.66, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$56.50 to \$56.66, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
6. The reporting person disclaims beneficial ownership of the securities of Jazz Pharmaceuticals plc held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P., except to the extent of his pecuniary interest therein.
7. These restricted stock units were granted pursuant to Jazz Pharmaceuticals plc's 2007 Equity Incentive Plan on August 9, 2012. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on August 9, 2013.

Signatures

/s/ Patrick G. Enright

** Signature of Reporting Person

01/11/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.